Peloton stands on a solid financial foundation, having raised more than $130M in venture capital support to date. Peloton benefits from strong backing by The Column Group, Remeditex Ventures, Tichenor Ventures, Topspin Fund, Nextech Invest, Foresite Capital and other investors. Peloton is well positioned to advance its promising therapies to proof of relevance clinical studies.
The Column Group is a leading venture capital firm based in San Francisco that seeks to partner with exceptional scientific founders, entrepreneurs, executives, and investment organizations with a shared vision for building the next generation of drug discovery and development companies. TCG invests in disease-focused drug discovery companies with the potential to become leaders in their respective fields. These companies are strongly supported by the unique and complementary skill sets of TCG’s team, which includes prominent authorities in the scientific, operational, and financial arenas.
Remeditex Ventures, a Dallas-based company, invests in high quality, innovative, early-stage biomedical projects that are judged to have commercialization potential. Its goal is to partner with early-stage researchers and entrepreneurs in Texas and Colorado, helping investigators establish commercial viability thereby making these ventures attractive to traditional investors.
TOPSPIN FUND, LP
Topspin Fund is a venture capital fund specializing in biotechnology and life sciences. It is managed by the principals of Topspin Partners, LP, funds that invest approximately $500 million in venture capital and buyouts.
Nextech Invest is a global investment manager founded in 1998 and located in Zurich, Switzerland. With its unique oncology-focused funds, it is a dedicated investor in leading oncology companies developing cancer drugs and diagnostics. Nextech Invest benefits from the support of an active and committed Scientific Advisory Board of highly influential oncology advisors.
Foresite Capital provides growth capital to emerging healthcare leaders with disruptive products and services, with the goal of transforming patient care.